Previous clinical trials did not show major increases in immune-related adverse events in older patients.

Limited available observational studies suggest that older and more vulnerable patients may be at a higher risk of immune-related adverse events and early treatment discontinuation.

Geriatric assessment could help identify older patients that will benefit from immune checkpoint inhibitors.